These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7424946)

  • 1. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status.
    Clemmons DR; Underwood LE; Ridgway EC; Kliman B; Kjellberg RN; Van Wyk JJ
    Am J Med; 1980 Oct; 69(4):571-5. PubMed ID: 7424946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly.
    Wass JA; Clemmons DR; Underwood LE; Barrow I; Besser GM; Van Wyk JJ
    Clin Endocrinol (Oxf); 1982 Oct; 17(4):369-77. PubMed ID: 6890417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of acromegaly by radioimmunoassay of somatomedin-C.
    Clemmons DR; Van Wyk JJ; Ridgway EC; Kliman B; Kjellberg RN; Underwood LE
    N Engl J Med; 1979 Nov; 301(21):1138-42. PubMed ID: 492275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactive somatomedin B in acromegaly and in Turner's syndrome.
    Benker G; Spira G; Zäh W; Tharandt L; Hackenberg K; Reinwein D
    Clin Endocrinol (Oxf); 1979 Oct; 11(4):357-65. PubMed ID: 519875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoassayable serum somatomedin B in normal subjects and in patients with acromegaly and pituitary dwarfism: effects of human growth hormone therapy.
    Wajchenberg BL; Liberman B; Gomes EN; Pieroni RR
    Horm Metab Res; 1980 Oct; 12(10):516-9. PubMed ID: 7439876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancies between bioassayable somatomedin activity and somatomedin C levels in acromegalic patients.
    Jasper HG; Artese R; Molocznik I; Bruno O
    Medicina (B Aires); 1986; 46(4):440-4. PubMed ID: 3574106
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.
    Furlanetto RW; Underwood LE; Van Wyk JJ; D'Ercole AJ
    J Clin Invest; 1977 Sep; 60(3):648-57. PubMed ID: 893668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunoassay of somatomedin B. Application to clinical and physiologic studies.
    Yalow RS; Hall K; Luft R
    J Clin Invest; 1975 Jan; 55(1):127-37. PubMed ID: 803217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromoergocryptin treatment of acromegaly persisting following conventional therapy.
    Holdaway IM; Frengley PA; Scott DJ; Ibbertson HK
    Clin Endocrinol (Oxf); 1978 Jan; 8(1):45-54. PubMed ID: 627091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of molecular forms of growth hormone in bromocriptine treated acromegaly in relation to changes of somatomedin-C and clinical response.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1985 Feb; 108(2):145-50. PubMed ID: 4038567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of somatomedins and growth hormone in relation to bone metabolism in acromegaly and thyroid dysfunction.
    Bijlsma JW; Duursma SA
    Clin Exp Rheumatol; 1986; 4(2):105-10. PubMed ID: 3731567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bromocriptine on serum hormones in acromegaly.
    Carlson HE; Levin SR; Braunstein GD; Spencer EM; Wilson SE; Hershman JM
    Horm Res; 1984; 19(3):142-52. PubMed ID: 6425186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly.
    Losa M; Oeckler R; Schopohl J; Müller OA; Alba-Lopez J; von Werder K
    J Neurosurg; 1989 Apr; 70(4):561-7. PubMed ID: 2647918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioassayable growth hormone activity in blood from healthy individuals and acromegalic patients.
    Thorngren KG; Hallengren B
    Acta Endocrinol (Copenh); 1986 Jan; 111(1):3-9. PubMed ID: 3946103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man.
    Wiedemann E; Schwartz E; Frantz AG
    J Clin Endocrinol Metab; 1976 May; 42(5):942-52. PubMed ID: 178687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin.
    Marek J; Srámková J; Schüllerová M; Stĕpán J; Schreiberová O
    Endokrinologie; 1981 Dec; 78(2-3):175-85. PubMed ID: 7037372
    [No Abstract]   [Full Text] [Related]  

  • 18. Criteria for the cure of acromegaly: comparison between basal growth hormone and somatomedin C plasma concentrations in active and non-active acromegalic patients.
    Giannella-Neto D; Wajchenberg BL; Mendonça BB; Almeida SF; Macchione M; Spencer EM
    J Endocrinol Invest; 1988 Jan; 11(1):57-60. PubMed ID: 3361077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen stimulates growth hormone and somatomedin-C in castrate and intact female baboons.
    Copeland KC; Johnson DM; Kuehl TJ; Castracane VD
    J Clin Endocrinol Metab; 1984 Apr; 58(4):698-703. PubMed ID: 6199364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.